VPC
NGNE icon

Vestal Point Capital’s Neurogene NGNE Stock Holding History

Vestal Point Capital’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-80,000
Closed -$1.83M – 76
2024
Q4 		$1.83M Buy
+80,000
New +$2.98M 0.11% 67

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vestal Point Capital's NGNE Position: Q1 2025 in Review

Vestal Point Capital sold out of Neurogene (NGNE) in Q1 2025, closing a stake of 80,000 shares — an estimated $1.83M sold.

Vestal Point Capital first reported a position in NGNE in Q4 2024 and held it in 1 quarter. The position peaked at $1.83M in Q4 2024. 85 funds tracked by Wall St. Rank hold NGNE as of Q1 2025.

  • Vestal Point Capital reported no remaining Neurogene position as of Q1 2025 after selling out during the quarter.
  • Vestal Point Capital sold 80,000 Neurogene shares in Q1 2025, an estimated $1.83M.
  • Vestal Point Capital first reported a position in Neurogene in Q4 2024 and held it in 1 quarter.
  • Vestal Point Capital's Neurogene position peaked at $1.83M in Q4 2024.
  • 85 funds tracked by Wall St. Rank held Neurogene as of Q1 2025.

Based on Vestal Point Capital's 13F filing for Q1 2025, filed 15 May 2025.